Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.57 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400257 | 0.90 | MGLL (0.72) | MGLLRAB9AENPP2MEN1KMT2A | |
| SCHEMBL9560058 | 0.88 | MGLL (0.62) | MGLLRAB9AHPGDENPP2KDM1A | |
| SCHEMBL13655148 | 0.88 | MGLL (0.65) | MGLLRAB9AENPP2KDM1AMAOA | |
| SCHEMBL882953 | 0.87 | MGLL (0.68) | MGLLRAB9AENPP2KDM1AMAOA | |
| SCHEMBL4961453 | 0.86 | MGLL (0.71) | MGLLRAB9AHPGDCYP1A2LMNA | |
| SCHEMBL1160238 | 0.85 | POLB (0.64) | MGLLRAB9ALMNAKMT2AKDM1A | |
| SCHEMBL4066082 | 0.85 | MGLL (0.65) | MGLLRAB9AENPP2KDM1AMAOA | |
| SCHEMBL10013766 | 0.84 | MGLL (0.61) | MGLLRAB9AHPGDENPP2KDM1A | |
| SCHEMBL15648038 | 0.84 | MGLL (0.72) | MGLLRAB9ALMNAENPP2 | |
| SCHEMBL5853166 | 0.84 | MGLL (0.72) | MGLLRAB9ALMNAENPP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108929263-B | Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-07-22 | — | — | CN | disclosed |
| CN-111108092-A | Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-05-05 | — | — | CN | disclosed |
| US-9975857-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975857-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2018-05-22 | — | — | US | disclosed |
| US-20150183746-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | UNIV NORTH CAROLINA STATE (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150183746-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | UNIV NORTH CAROLINA STATE (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150183746-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | UNIV NORTH CAROLINA STATE (US) | 2015-07-02 | — | — | US | disclosed |
| US-9005643-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2015-04-14 | — | — | US | disclosed |
| US-9005643-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2015-04-14 | — | — | US | disclosed |
| US-9005643-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2015-04-14 | — | — | US | disclosed |
| US-20090270475-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270475-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009123753-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009123753-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270475-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | TFPI, O60361, PGLS | MGLL 404/4885RAB9A 1842/4885HPGD 890/4885 |
| US-20150183746-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | TFPI, O60361, PGLS | MGLL 404/4885RAB9A 1842/4885HPGD 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.